Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Hematologic Neoplasms 2COVID-19 2Respiratory Sounds 1Pharmacokinetics 1Neoplasms 1Lymphoma, Follicular 1Crohn Disease 1Bronchiolitis Obliterans Syndrome 1Asthma 1

Interventions

Cyclophosphamide 41fludarabine 35Tacrolimus 28Mycophenolic Acid 27Whole-Body Irradiation 25Busulfan 24fludarabine phosphate 21Melphalan 19thymoglobulin 16Antilymphocyte Serum 16Methotrexate 13Thiotepa 12Stem Cell Transplantation 9Rituximab 9Granulocyte Colony-Stimulating Factor 9Filgrastim 8Cyclosporine 8trametinib 7Sirolimus 7Nivolumab 5ruxolitinib 4merphos 4Peripheral Blood Stem Cell Transplantation 4Cytarabine 4Cord Blood Stem Cell Transplantation 4Bendamustine Hydrochloride 4tocilizumab 3itacitinib 3fedratinib 3dabrafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Hematologic Neoplasms × Azithromycin × Clear all
NCT04294641 2026-01-23

Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
10 enrolled 15 charts
Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms

NCT04392128 2020-09-04

HYACINTHE

Institut de cancérologie Strasbourg Europe

Phase 2 Withdrawn
Other hematologic neoplasm

COVID-19, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡